Loading stock data…
Q32 Bio Inc (QTTB)
$14.14+0.97 (+7.37%)
After Hours$15.00+0.86 (+6.08%)· Last close Jun 29
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Q32 Bio Inc. in the Healthcare sector is trading at $14.14 with a market capitalization of $214M. Wall Street consensus targets $14.25 (4 analysts), implying a +0.8% move over the next 12 months. The stock is currently near its 52-week high of $15.02, remaining 182.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $53.74M | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.72M↓ | $45.88M↑ | -$7.58M↑ | -$9.17M↑ | -$12.23M |
| Net Income | -$7.61M↓ | $57.73M↑ | -$7.39M↑ | -$9.49M↑ | -$11.03M |
Peer Comparison
JNJUNHPFE
Fundamentals
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$214.50M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
71.78%
Volume
Today's trading volume
712,389
Recent News
QTTB Stock Hits 18-Month High, Heads Toward Recording Its Best Ever Month – What’s Driving The Investor Optimism?
The biotech firm unveiled a $55 million private placement priced at a 13% premium to the previous session’s close.
Q32 Bio Secures $55 Million Private Placement to Advance Alopecia Areata Pipeline (QTTB)
Q32 Bio raised approximately $55 million in a private placement led by major healthcare investors as the company continues development of its Phase 2 alopecia areata therapy program. Key Investor TakeawaysQ32 Bio (NASDAQ:QTTB) announced a $55 million private placement involving institutional and accredited investors.
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 145.69%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 145.7% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade
The consensus price target hints at a 163.4% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026.